Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119)
An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing
🩺 Plain-English Summary (8th-Grade Level)
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Who can join: Review the eligibility criteria below.
Location: Banner Health — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- Apheresis (OTHER)
- Next Generation Sequencing (NGS) (DIAGNOSTIC_TEST)
- Long Range NGS HLA typing (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Banner Health — Gilbert, Arizona
- Mayo Clinic Hospital — Phoenix, Arizona
- City of Hope — Duarte, California
- University of California San Diego — La Jolla, California
- Stanford University — Palo Alto, California
- UCLA Medical Center — Santa Monica, California
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Massachusetts General Hospital/Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- Washington University — St Louis, Missouri
- NYU Langone Medical Center — New York, New York
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Vanderbilt University Medical Center — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (310) 431-9180
Email: ClinicalTrials@a2bio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial — Scottsdale, Arizona
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression — Gilbert, Arizona
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.